Lebrikizumab
Lebrikizumab (TNX-650) is an IgG4 humanized anti-interleukin-13 (IL-13) mAb with anti-itch effects that specifically binds to IL-13 in a non-receptor binding domain and inhibits its function. Lebrikizumab inhibits the IL-13 driven Th2 inflammatory response and blocks the signaling of IL-4Rα/IL-13Rα1. Lebrikizumab can be used for the research of asthma, atopic dermatitis and neuroinflammatory diseases1,2,3.
Product Specifications
Background
Endotoxin
< 0.5 EU/mg
Purity
≥ 90%
Format
Aqueous buffer solution.
Shipping Conditions
-80°C
Storage Conditions
Store at -80°C for 2 years. Aliquots should be stored at the same temperature after first use to avoid multiple freeze-thaws.
Calculated Molecular Weight
49/23 kDa
Formulation
Supplied as a 0.22 μm filtered solution in PBS, pH 7.4.
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items